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Introduction {#rcr2402-sec-0001}
============

Resistance mechanisms to osimertinib are of two types: epidermal growth factor receptor (*EGFR*) dependent, such as point mutations containing C797S, and *EGFR* independent, such as bypass signal pathway or histological transformation to small‐cell lung carcinoma (SCLC) and large‐cell neuroendocrine carcinoma (LCNEC)) [1](#rcr2402-bib-0001){ref-type="ref"}, [2](#rcr2402-bib-0002){ref-type="ref"}. Here, we report an autopsy case with *EGFR* T790M‐positive adenosquamous carcinoma that transformed to *EGFR* T790M‐negative SCLC and LCNEC after osimertinib therapy.

Case Report {#rcr2402-sec-0002}
===========

A 59‐year‐old man underwent video‐assisted thoracic surgery of the left upper lobe with ND2a‐1 lymphadenectomy 4 years prior to disease presentation and was diagnosed as having stage IA (T1bN0M0) adenosquamous carcinoma of the lung (Fig. [1](#rcr2402-fig-0001){ref-type="fig"}A--C) harbouring *EGFR* exon 19 deletion based on the American Joint Committee on Cancer staging system, seventh edition. He was a non‐smoker with no previous medical problems. Two years after the surgery, he was diagnosed as having recurrence in the mediastinal lymph nodes and left anterior chest wall. Erlotinib (150 mg once daily) and bevacizumab (15 mg/kg every 3 weeks) were started as first‐line therapy. After 19 months of the therapy, the lung cancer also metastasized to the right supraclavicular lymph node. He underwent percutaneous supraclavicular lymph node needle biopsy as the first‐repeat biopsy. Adenosquamous carcinoma harbouring *EGFR* exon 19 deletion and T790M mutation was detected. Osimertinib (80 mg once daily) was started, and the patient achieved partial response. Seven months after starting treatment with osimertinib, the mediastinal lymphadenopathy recurred, and multiple new liver metastases were seen. The second‐repeat biopsy for the subcarinal mediastinal lymph nodes was performed. The histological diagnosis was SCLC harbouring *EGFR* exon 19 deletion without T790M mutation (Fig. [1](#rcr2402-fig-0001){ref-type="fig"}D--F). He was treated with combination chemotherapy of cisplatin (80 mg/m^2^, day 1, every 3 weeks) and etoposide (100 mg/m^2^, days 1--3, every 3 weeks). After one cycle of chemotherapy, computed tomography (CT) imaging demonstrated that the mediastinal lymph nodes had shrunk, but the hepatic metastases had disseminated. Fine‐needle aspiration biopsy of the liver was performed, and the histological diagnosis was also SCLC harbouring *EGFR* exon 19 deletion without T790M mutation (Fig. [1](#rcr2402-fig-0001){ref-type="fig"}G--I). After four cycles of chemotherapy, the size of the mediastinal lymph nodes further decreased, but the hepatic metastases increased.

![Histology of lung surgical specimen (A--C); (A) haematoxylin and eosin, (B) TTF‐1 and CK5/6, and (C) p40 and napsin stains. Histology of endobronchial ultrasound‐guided transbronchial needle aspiration specimens from mediastinal lymph nodes (D--F); (D) Haematoxylin and eosin, (E) synaptophysin, and (F) CD56 stains. Histology of liver biopsy (G--I), (G) Haematoxylin and eosin, (H) synaptophysin, and (I) CD56 stains.](RCR2-7-na-g001){#rcr2402-fig-0001}

Two months later, liver metastases became worse, and new lesions of the bone metastases at spine developed. We administered amrubicin (35 mg/m^2^, 75% on days 1--3, every 3 weeks) for the next treatment. However, the treatment was changed to irinotecan (100 mg/m^2^, 75% on day 1, 8, and 15 every 4 weeks) after one cycle of amrubicin because of elevated liver enzymes and pancytopenia. After two cycles of irinotecan, he developed superior vena cava syndrome, which was treated with radiotherapy. He was died 13 months after diagnosis of transformation to SCLC. An autopsy was performed, and microscopic examination showed metastases to lungs, mediastinum, cervical lymph nodes, liver, left kidney, right adrenal gland, bones, and epicardium. Microscopic examination demonstrated tumour heterogeneity of various organs. Although histological types of most metastatic lesions were SCLC or LCNEC, adenocarcinoma was found in the left kidney, coexistence of adenosquamous carcinoma and SCLC was observed in mediastinum, and adenocarcinoma and SCLC were found in right adrenal gland and cervical lymph nodes (Fig. [2](#rcr2402-fig-0002){ref-type="fig"}). LCNEC of epicardium also showed *EGFR* exon 19 deletion without T790M mutation.

![Histology of autopsy (A--H); (A) haematoxylin and eosin staining of adenosquamous carcinoma component, (B) TTF‐1 and CK5/6 stains, (C) p40 and napsin stains, (D) haematoxylin and eosin staining of small cell carcinoma component, (E) haematoxylin and eosin staining of large‐cell neuroendocrine carcinoma component, (F) TTF‐1 stain, (G) synaptophysin stain, and (H) CD56 stain.](RCR2-7-na-g002){#rcr2402-fig-0002}

Discussion {#rcr2402-sec-0003}
==========

We report a patient with *EGFR* T790M‐positive adenosquamous carcinoma that transformed to *EGFR* T790M‐negative SCLC and LCNEC after treatment with osimertinib. *EGFR* exon 19 deletion was detected in both adenosquamous carcinoma and SCLC.

SCLC transformation following treatment with first‐and second‐generation EGFR‐tyrosine kinase inhibitors (TKIs) has been reported in 3--15% of patients [2](#rcr2402-bib-0002){ref-type="ref"}, [3](#rcr2402-bib-0003){ref-type="ref"}. As in cases of adenocarcinoma changing to SCLC, the inactivation of retinoblastoma 1 (*RB1*) and tumour protein 53 (*TP53*) were also reported [4](#rcr2402-bib-0004){ref-type="ref"}, [5](#rcr2402-bib-0005){ref-type="ref"}.

SCLC transformation due to osimertinib is rare, and its frequency is still unknown. To our knowledge, only nine cases of SCLC transformation after osimertinib treatment have been reported [6](#rcr2402-bib-0006){ref-type="ref"}, [7](#rcr2402-bib-0007){ref-type="ref"}, [8](#rcr2402-bib-0008){ref-type="ref"}, [9](#rcr2402-bib-0009){ref-type="ref"}, [10](#rcr2402-bib-0010){ref-type="ref"} (Table [1](#rcr2402-tbl-0001){ref-type="table"}).

###### 

Previous reports with transformation of non‐small‐cell lung adenocarcinoma to small‐cell lung carcinoma (SCLC) and large‐cell neuroendocrine carcinoma (LCNEC) following osimertinib therapy.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                   Gender     Age Stage        Histology at diagnosis    EGFR status at diagnosis  EGFR‐TKIs before osimertinib   EGFR status after first re‐biopsy   Detection    Best response with osimertinib   Response duration (months)  Histology after second re‐biopsy   EGFR status after second re‐biopsy   Treatment
  ---- ----------------------------------------------------------- -------- ----- ------------ ------------------------ -------------------------- ------------------------------ ----------------------------------- ----------- -------------------------------- ---------------------------- ---------------------------------- ------------------------------------ -----------------
  1    Kim et al. [6](#rcr2402-bib-0006){ref-type="ref"}           Female      57 ND           Ad                                 19 del           Gefitinib                      19 del +\                           Tissue                     PR                             11              SCLC                               19 del +\                            Radiation\
                                                                                                                                                                                  T790M +                                                                                                                                          T790M −                              CBDCA+VP16

  2    Ham et al. [7](#rcr2402-bib-0007){ref-type="ref"}           Female      57 cT3N2M1a\    Ad                                 L858R            Erlotinib                      L858R +\                            Tissue                     PR                             14              SCLC                               L858R +\                             CBDCA+VP16
                                                                                  IVa                                                                                             T790M +                                                                                                                                          T790M −\                             
                                                                                                                                                                                                                                                                                                                                   EGFR amp                             

  3    Ham et al. [7](#rcr2402-bib-0007){ref-type="ref"}           Female      58 Reccurent    Ad                                  Wild            Erlotinib\                     19 del +\                           Tissue                     PR                             18              SCLC                               19 del +\                            CBDCA+VP16
                                                                                                                                                   Afatinib                       T790M +                                                                                                                                          T790M −                              

  4    Li et al. [8](#rcr2402-bib-0008){ref-type="ref"}            Female      52 Reccurent    Ad                                 19 del           Erlotinib                      19 del −\                           Plasma                     PR                             6               SCLC                               19 del +\                            CBDCA+VP16\
                                                                                                                                                                                  T790M −                                                                                                                                          T790M −                              +osimertinib

  5    Minari et al. [9](#rcr2402-bib-0009){ref-type="ref"}        Male        69 ND           Ad                                 19 del           Afatinib                       19 del +\                           Plasma                     PD                             3               SCLC                               19 del −\                            BSC
                                                                                                                                                                                  T790M +                                                                                                                                          T790M −                              

  6    Minari et al. [9](#rcr2402-bib-0009){ref-type="ref"}        Female      70 ND           Ad                                 19 del           Afatinib                       19 del +\                           Plasma                     PD                             2               SCLC                               19 del +\                            BSC
                                                                                                                                                                                  T790M +                                                                                                                                          T790M −                              

  7    Minari et al. [9](#rcr2402-bib-0009){ref-type="ref"}        Male        55 ND           Ad                                 19 del           Gefitinib                      19 del +\                           Plasma                     PD                             3               SCLC                               19 del +\                            CBDCA+VP16
                                                                                                                                                                                  T790M +                                                                                                                                          T790M −                              

  8    Minari et al. [9](#rcr2402-bib-0009){ref-type="ref"}        Male        68 ND           Ad                                 L858R            Afatinib                       L858R +\                            Plasma                     PD                             3               SCLC                               L858R +\                             CBDCA+VP16
                                                                                                                                                                                  T790M +                                                                                                                                          T790M −                              

  9    Taniguchi et al. [10](#rcr2402-bib-0010){ref-type="ref"}    Female      67 Reccurent    Ad                                 19 del           Gefitinib\                     L858R +\                            Tissue                     ND                             13              SCLC                               19 del +\                            CBDCA+VP16
                                                                                                                                                   Erlotinib                      T790M +                                                                                                                                          T790M −                              

  10   Baglivo S, et al. [11](#rcr2402-bib-0011){ref-type="ref"}   Male        57 cT1bN2Mab\   Ad                                 19 del           Erlotinib                      19 del +\                           Tissue                     1                              PD              LCNEC                              19 del +\                            Radiation\
                                                                                  IVb                                                                                             T790M +                                                                                                                                          T790M −                              Adrrenalectomy\
                                                                                                                                                                                                                                                                                                                                                                        CDDP+VP16

  11   Ricordel et al. [12](#rcr2402-bib-0012){ref-type="ref"}     Male        57 cT3N2M1b\    Ad                                 19 del           Gefitinib                      19 del +\                           Tissue                     SD                             10              LCNEC                              19 del +\                            Radiation\
                                                                                  IVb                                                                                             T790M +                                                                                                                                          T790M +                              Osimertinib

       This case                                                   Male        63 Reccurent    Ad‐Sq                              19 del           Erlotinib+Bev                  19 del +\                           Tissue                     PR                             7               SCLC and LCNEC                     19 del +\                            CDDP+VP16
                                                                                                                                                                                  T790M +                                                                                                                                          T790M −                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

19 del, exon 19 deletion; Ad, adenocarcinoma; Ad‐Sq, adenosquamous cell carcinoma; BSC, best supportive care; CBDCA, carboplatin; CDDP, cisplatin; L858R, L858R point mutation; ND, not described; PD, progressive disease; PR, partial response; SD, stable disease; T790M, T790M point mutation; VP16, etoposide.

In the autopsy findings of this case, LCNEC was also found along with SCLC. Several cases with transformation from adenocarcinoma to LCNEC were reported as a resistant mechanism to the first‐ and second‐generation EGFR‐TKIs along with two cases to osimertinib (Table [1](#rcr2402-tbl-0001){ref-type="table"}) [11](#rcr2402-bib-0011){ref-type="ref"}, [12](#rcr2402-bib-0012){ref-type="ref"}. LCNEC was a very heterogeneous group. A next‐generation sequencing (NGS) study of LCNEC from the Memorial Sloan Kettering Cancer Center showed that 18 of 45 LCNEC cases had SCLC‐like molecular profile, but 25 had non‐small cell lung carcinoma (NSCLC)‐like molecular profile [13](#rcr2402-bib-0013){ref-type="ref"}. These data made sense to us because LCNEC coexisted in our case, transforming from adenosquamous carcinoma to SCLC.

Several studies showed heterogeneity of acquired resistance to EGFR‐TKIs. Because the heterogeneity of expression of immune markers depends on the metastatic sites and histological transformation, and the biopsy of one lesion may not represent the immune marker status of all lesions [14](#rcr2402-bib-0014){ref-type="ref"}. In this case, we conducted second‐repeat biopsies from two metastatic sites (mediastinal lymph nodes and liver), which resulted in an observation of SCLC with *EGFR* exon 19 deletion without T790M mutation. However, the results on both biopsies were a little different from autopsy findings, a strange mix of SCLC, LCNEC, and adenocarcinoma. This result showed limitation of small biopsies and usefulness of repeated biopsies from different sites to accumulate information for a clinical decision.

Identifying the histological diagnosis and driver mutations is important in deciding treatment options. Given the various mechanisms of acquired resistance, repeat biopsy at the time of disease progression is useful to guide the direction of subsequent treatment in patients with *EGFR* mutation‐positive lung cancer.
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